查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2048065

琥珀酸美托洛爾市場－全球產業規模、佔有率、趨勢、機會和預測：銷售管道、最終用途、地區和競爭格局分類，2021-2031年

Metoprolol Succinate Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

琥珀酸美托洛爾是一種BETA1選擇性腎上腺素受體阻斷劑，透過調節心率和心摶出量來治療高血壓、心絞痛和慢性心臟衰竭。預計到2025年，琥珀酸美托洛爾的全球市場規模將從3.9112億美元成長到2031年的5.8401億美元。

這一成長主要受全球慢性心血管疾病盛行率上升和人口老化的影響，這兩者都需要持續的長期治療性介入來降低死亡率。年複合成長率為6.91%。例如，根據歐洲心臟學會（ESC）的報告，到2024年，心血管疾病將佔成員國年度死亡總數的37.4%，凸顯了成熟藥物療法的關鍵作用。

市場概覽
預測期 2027-2031
市場規模：2025年 3.9112億美元
市場規模：2031年 5.8401億美元
複合年成長率：2026-2031年 6.91%
成長最快的細分市場 直接地
最大的市場 亞太地區

市場需求依然強勁，但供應鏈穩定性和生產品質方面面臨嚴峻挑戰。近期監管機構對非專利藥製劑中雜質的嚴格檢查導致產品召回和生產延誤，阻礙了琥珀酸美托洛爾全球供應的穩定和進一步擴大。

市場促進因素

慢性心血管疾病盛行率的不斷上升是推動市場擴張的主要動力，也因此對用於治療高血壓和心臟衰竭的BETA阻斷劑（如琥珀酸美托洛爾）的需求持續成長。由於這些慢性疾病需要長期服藥以預防嚴重心血管事件，患者數量的增加直接轉化為處方量的增加。近期健康統計數據凸顯了受影響人群的龐大規模；美國心臟協會 (AHA) 在 2024 年 1 月報告稱，預計美國將有 1.279 億成年人患有某種形式的心血管疾病。如此廣泛的發病率鞏固了琥珀酸美托洛爾作為全球重要治療藥物的地位。

同時，價格低廉的學名藥的廣泛普及擴大了這些重要藥物的可及性，但也帶來了生產品質和供應鏈韌性方面的挑戰。學名藥透過提供經濟有效的治療方案擴大了市場規模，但大規模生產的需求也使得品質標準無法一致地得到滿足時，便會造成脆弱性。例如，2024年6月，美國食品藥物管理局（FDA）報告稱，Granules Pharmaceuticals公司自願召回了超過33,000片琥珀酸美托洛爾緩釋片，原因是這些藥品不符合溶解度規格。此類供應中斷反映了整個行業面臨的更廣泛的壓力。根據美國衛生系統藥劑師協會統計，2024年4月，美國活性成分短缺的數量達到了創紀錄的323種，凸顯了健全的供應鏈對於維持非專利市場的重要性。

市場挑戰

全球琥珀酸美托洛爾市場成長的主要障礙在於供應鏈韌性與嚴格的生產品質要求之間的微妙平衡。隨著有關雜質和溶出均勻性的監管指南日益嚴格，製造商越來越難以維持符合法規的連續生產週期。這種日益嚴格的審查導致製劑缺陷頻繁被發現，進而造成分銷立即中斷。此類中斷擾亂了藥品的穩定供應，削弱了處方醫生的信心，並迫使醫療系統尋找替代藥物。因此，現有製劑的市佔率和收入潛力均有所下降。

近期發生的供應鏈事件清楚地顯示了此類中斷的影響。 2025年6月，美國食品藥物管理局（FDA）召回了超過33,000片琥珀酸美托洛爾緩釋片，原因是生產過程中出現重大偏差，導致產品溶解度不符合規格。這項品管失誤凸顯了製造業固有的不穩定性，任何一項監管違規都可能導致大量產品被召回。因此，如果產品品質和供應無法得到可靠保障，市場滿足日益成長的全球患者群體需求的能力將受到阻礙。

市場趨勢

製藥公司正日益專注於研發和推出琥珀酸美托洛爾與其他抗高血壓藥物（如氨氯地平和氫氯噻嗪）的單藥複方組合藥物，旨在提高患者的用藥依從性和臨床療效。此策略旨在減輕合併糖尿病和心臟衰竭等疾病患者的用藥負擔，並透過整合劑型簡化慢性病管理。製藥公司正積極尋求這些複雜製劑的監管核准，以擴大其在心血管治療市場的佔有率。例如，《醫學對話》（Medical Dialogues）在2025年7月報道稱，印度藥品監管機構通過專家委員會核准了Zydus Healthcare公司開展Empagliflozin和琥珀酸美托洛爾固定劑量組合藥物III期臨床試驗的申請。這顯示製藥業對這種治療方法的重視。

此外，全球製藥公司正逐步在包括印度和中國在內的快速成長的新興市場建立生產設施並建立策略合作夥伴關係。此舉旨在降低生產成本並滿足當地市場需求。這種在地化策略使公司能夠利用專門的大規模生產能力生產複雜的學名藥，從而可靠地向國內外消費者供應價格合理的藥品。這種業務營運模式轉變的成效體現在主要製造地出口量的顯著成長。根據《新印度快報》2025年7月報道，印度2025會計年度的藥品出口額成長了9.3%，達到創紀錄的305億美元。這主要得益於複雜學名藥產業的成長，包括美托洛爾琥珀酸鹽等緩釋製劑。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球琥珀酸美托洛爾市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 銷售管道（直接、間接）
    • 依應用領域（高血壓、慢性心臟衰竭、心絞痛、心律不整、焦慮症等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美琥珀酸美托洛爾市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲琥珀酸美托洛爾市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區琥珀酸美托洛爾市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲琥珀酸美托洛爾市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：琥珀酸美托洛爾在南美洲的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球琥珀酸美托洛爾市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Granules India Limited
  • Surya Remedies Private Limited
  • Shubham Remedies
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories
  • ATUL BIOSCIENCE LTD
  • UNITED CHEMIE PVT LTD
  • Vasoya Industries Pvt. Ltd
  • Infocus Remedies Pvt Ltd
  • Alembic Pharmaceuticals Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 28611

The global market for Metoprolol Succinate, a beta1-selective adrenoceptor blocker used to manage hypertension, angina pectoris, and chronic heart failure by regulating heart rate and cardiac output, is projected to expand from USD 391.12 Million in 2025 to USD 584.01 Million by 2031, demonstrating a compound annual growth rate (CAGR) of 6.91%. This growth is primarily fueled by the increasing worldwide incidence of chronic cardiovascular conditions and a growing elderly population, both requiring ongoing, long-term therapeutic interventions to reduce mortality. For instance, the European Society of Cardiology reported that cardiovascular disease caused 37.4% of all annual deaths in its member countries in 2024, highlighting the essential role of proven pharmacological treatments.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 391.12 Million
Market Size 2031USD 584.01 Million
CAGR 2026-20316.91%
Fastest Growing SegmentDirect
Largest MarketAsia Pacific

While demand remains strong, the market confronts considerable challenges related to supply chain stability and manufacturing quality. Recent rigorous regulatory examinations of impurities in generic formulations have led to product recalls and manufacturing setbacks, posing barriers to the consistent global availability and broader expansion of Metoprolol Succinate supplies.

Market Driver

The increasing prevalence of chronic cardiovascular conditions is the main force propelling market expansion, generating consistent demand for beta-blockers such as metoprolol succinate for managing hypertension and heart failure. Since these chronic illnesses necessitate long-term medication adherence to prevent severe cardiac events, a growing patient base directly translates to higher prescription volumes. Recent health statistics underscore the vast scale of the affected population, with the American Heart Association reporting in January 2024 that an estimated 127.9 million adults in the United States had some form of cardiovascular disease. This widespread occurrence solidifies metoprolol succinate's role as a fundamental treatment globally.

Simultaneously, the widespread availability of affordable generic drug alternatives has broadened access to this vital medication, though it has also introduced challenges concerning manufacturing quality and supply chain resilience. While generics boost market volume by providing cost-effective treatment options, the necessity for high-volume production creates susceptibilities when quality benchmarks are not consistently met. An example of this vulnerability occurred in June 2024 when Granules Pharmaceuticals voluntarily recalled over 33,000 bottles of Metoprolol Succinate Extended-Release Tablets due to failed dissolution specifications, as reported by the US Food and Drug Administration. Such interruptions reflect wider industry pressures, with active drug shortages in the US reaching a record 323 in April 2024, according to the American Society of Health-System Pharmacists, emphasizing the crucial need for resilient supply chains to sustain the generic market.

Market Challenge

The principal obstacle impeding the growth of the Global Metoprolol Succinate Market stems from the delicate balance of supply chain resilience combined with stringent manufacturing quality requirements. As regulatory guidelines concerning impurities and dissolution consistency become more rigorous, manufacturers face escalating difficulties in sustaining compliant and continuous production cycles. This intensified oversight frequently reveals formulation flaws, leading to immediate distribution halts. Such interruptions disrupt the steady availability of the drug, diminishing prescriber trust and compelling healthcare systems to secure alternative medications, which consequently reduces the market share and revenue potential for established formulations.

The impact of these disruptions is clearly demonstrated by recent supply chain incidents. In June 2025, a notable manufacturing deviation prompted the U.S. Food and Drug Administration to recall over 33,000 bottles of Metoprolol Succinate Extended-Release Tablets due to inadequate dissolution specifications. This particular quality control failure highlights the inherent instability within the manufacturing sector, where a single regulatory non-compliance can remove a substantial quantity of product from circulation. Therefore, the consistent inability to assure product quality and volume hinders the market's capacity to reliably cater to the growing global patient population.

Market Trends

Pharmaceutical firms are increasingly focusing on developing and introducing single-pill combinations that include Metoprolol Succinate alongside other antihypertensive agents, such as amlodipine or hydrochlorothiazide, aiming to improve patient adherence and clinical effectiveness. This strategy seeks to alleviate the pill burden for patients suffering from co-occurring conditions like diabetes and heart failure, thereby simplifying chronic disease management through consolidated dosage forms. Manufacturers are actively seeking regulatory approvals for these intricate formulations to secure a greater share of the cardiovascular therapeutic market. For example, Medical Dialogues reported in July 2025 that India's drug regulator, through its Subject Expert Committee, approved Zydus Healthcare's request to proceed with Phase III clinical trials for a fixed-dose combination of Empagliflozin and Metoprolol Succinate, underscoring the industry's dedication to this therapeutic approach.

Furthermore, global pharmaceutical companies are progressively setting up manufacturing facilities and forging strategic alliances in rapidly expanding emerging markets, including India and China. This move aims to reduce production expenses and tap into local market demand. This localization approach enables companies to utilize specialized, large-scale production capacities for complex generics, ensuring a consistent supply of affordable medications for both domestic and international consumers. The effectiveness of this operational change is reflected in the substantial increase in export volumes from major manufacturing centers. As per The New Indian Express in July 2025, India's pharmaceutical exports soared by 9.3% to a record USD 30.5 billion in the 2025 fiscal year, largely propelled by the growth of the complex generics sector, which encompasses advanced extended-release formulations like Metoprolol Succinate.

Key Market Players

  • Granules India Limited
  • Surya Remedies Private Limited
  • Shubham Remedies
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories
  • ATUL BIOSCIENCE LTD
  • UNITED CHEMIE PVT LTD
  • Vasoya Industries Pvt. Ltd
  • Infocus Remedies Pvt Ltd
  • Alembic Pharmaceuticals Ltd

Report Scope

In this report, the Global Metoprolol Succinate Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Metoprolol Succinate Market, By Sales Channel

  • Direct
  • Indirect

Metoprolol Succinate Market, By End Use

  • Hypertension
  • Chronic Heart Failure
  • Angina Pectoris
  • Arrhythmias
  • Anxiety
  • Others

Metoprolol Succinate Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Metoprolol Succinate Market.

Available Customizations:

Global Metoprolol Succinate Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Metoprolol Succinate Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sales Channel (Direct, Indirect)
    • 5.2.2. By End Use (Hypertension, Chronic Heart Failure, Angina Pectoris, Arrhythmias, Anxiety, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Metoprolol Succinate Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sales Channel
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Metoprolol Succinate Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sales Channel
        • 6.3.1.2.2. By End Use
    • 6.3.2. Canada Metoprolol Succinate Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sales Channel
        • 6.3.2.2.2. By End Use
    • 6.3.3. Mexico Metoprolol Succinate Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sales Channel
        • 6.3.3.2.2. By End Use

7. Europe Metoprolol Succinate Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sales Channel
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Metoprolol Succinate Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sales Channel
        • 7.3.1.2.2. By End Use
    • 7.3.2. France Metoprolol Succinate Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sales Channel
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Metoprolol Succinate Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sales Channel
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Metoprolol Succinate Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sales Channel
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Metoprolol Succinate Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sales Channel
        • 7.3.5.2.2. By End Use

8. Asia Pacific Metoprolol Succinate Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sales Channel
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Metoprolol Succinate Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sales Channel
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Metoprolol Succinate Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sales Channel
        • 8.3.2.2.2. By End Use
    • 8.3.3. Japan Metoprolol Succinate Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sales Channel
        • 8.3.3.2.2. By End Use
    • 8.3.4. South Korea Metoprolol Succinate Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sales Channel
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Metoprolol Succinate Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sales Channel
        • 8.3.5.2.2. By End Use

9. Middle East & Africa Metoprolol Succinate Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sales Channel
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Metoprolol Succinate Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sales Channel
        • 9.3.1.2.2. By End Use
    • 9.3.2. UAE Metoprolol Succinate Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sales Channel
        • 9.3.2.2.2. By End Use
    • 9.3.3. South Africa Metoprolol Succinate Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sales Channel
        • 9.3.3.2.2. By End Use

10. South America Metoprolol Succinate Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sales Channel
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Metoprolol Succinate Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sales Channel
        • 10.3.1.2.2. By End Use
    • 10.3.2. Colombia Metoprolol Succinate Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sales Channel
        • 10.3.2.2.2. By End Use
    • 10.3.3. Argentina Metoprolol Succinate Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sales Channel
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Metoprolol Succinate Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Granules India Limited
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Surya Remedies Private Limited
  • 15.3. Shubham Remedies
  • 15.4. Sun Pharmaceutical Industries Ltd.
  • 15.5. Dr. Reddy's Laboratories
  • 15.6. ATUL BIOSCIENCE LTD
  • 15.7. UNITED CHEMIE PVT LTD
  • 15.8. Vasoya Industries Pvt. Ltd
  • 15.9. Infocus Remedies Pvt Ltd
  • 15.10. Alembic Pharmaceuticals Ltd

16. Strategic Recommendations

17. About Us & Disclaimer